pharmaphorum

SEPTEMBER 22, 2022

The company said this morning that US sales growth is its main priority, and that it will be led in the near-term by “high-value” new drugs Kisqali (ribociclib), iptacopan, Pluvicto (lutetium Lu 177 vipivotide tetraxetan), remibrutinib, and Scemblix (asciminib). billion by 2024.

Management 52

Management Sales Patients Marketing 52

pharmaphorum

SEPTEMBER 23, 2022

In a statement , Ionis said that AZD8233 met its objectives in the phase 2b SOLANO trial in patients with hypercholesterolaemia, when given as a monthly 60mg dose, reducing LDL-C levels by 62% compared to placebo after 28 weeks, and thereby achieving the study’s primary endpoint. billion in sales by 2027, ahead of Repatha at $2.2

Sales 59

Sales Education Pharma Patients 59

Pharmaceutical Technology

DECEMBER 16, 2022

GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. of 7MM sales.

Marketing 59

Marketing Side effects Sales Safety 59

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Top companies and drugs by sales in 2021. 2022;21(4):251–.

Food and Drug Administration 105

Food and Drug Administration Manufacturing Safety Pharmaceutical 105

pharmaphorum

OCTOBER 6, 2022

Lilly already has approval for the dual GLP-1/GIP agonist under the Mounjaro brand name as a diabetes therapy and is tipped to make rapid inroads in that market, with EvaluatePharma predicting sales could break the $1 billion barrier in 2024, and $3 billion two years later. billion in 2025 sales.

Sales 52

Sales Marketing FDA Leads 52

pharmaphorum

JANUARY 9, 2023

Albireo secured approval in the US and Europe for the ileal bile acid transport inhibitor (IBATi) drug in 2021 for the treatment of pruritus (itching) in patients with rare disorder progressive familial intrahepatic cholestasis (PFIC), and has said sales should reach $24 million this year. billion deal.

Transportation 52

Transportation Sales Leads FDA 52

pharmaphorum

JULY 18, 2022

. “The acceptance of the filing of proposed biosimilar natalizumab by the European regulatory authorities means we are a critical step closer to getting this important medicine to the patients who need it the most,” said Polpharma Biologics’ chief executive Michael Soldan in a statement.

Competition 52

Competition Marketing Sales Medicine 52

pharmaphorum

OCTOBER 1, 2022

Sales in the first half of this year fell 19% to $1.16 The latest judgments relate to an attempt by Chinese drugmaker HEC Pharma to bring a generic version of fingolimod to market in the US, and Novartis defense of the 9,187, 405 patent which expires in December 2027. Gilenya made revenues of $2.8

Competition 52

Competition Pharma Marketing Sales 52

pharmaphorum

NOVEMBER 18, 2022

At its second attempt, Provention Bio has secured FDA approval for teplizumab, as a treatment to delay late-stage type 1 diabetes (T1D) in at-risk individuals – becoming the first disease-modifying therapy for these patients. Teplizumab is thought to work by preventing the activation of T cells that attack those cells.

FDA 52

FDA Patients Manufacturing Sales 52

Legacy MEDSearch

SEPTEMBER 20, 2022

The SavvyWire is the first and only Sensor-Guided TAVR solution, designed to support TAVR efficiency and lifetime patient management. The TAVR procedure was initially only indicated for inoperable patients with severe symptomatic aortic stenosis, and later for patients at high surgical risk. About OpSens Inc.

FDA 52

FDA Food and Drug Administration Recruitment Physicians 52

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach. million in Q3.

Medical 105

Medical Manufacturing Insurance Side effects 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach. million in Q3.

Medical 98

Medical Manufacturing Insurance Side effects 98

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.” Impact Beyond Medicare The IRA won’t just impact negotiation with the government either.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Clarivate

AUGUST 27, 2024

and ramped up sales of PFA systems in Europe. Based on brisk uptake in the latter half of the first quarter, it appeared that PFA would account for at least 30% of the ablation market and $1 billion in sales by the end of 2024. Since the FDA’s approval of the first pulsed field ablation (PFA) system in the U.S. s Farapulse.

Marketing 52

Marketing FDA Competition Medical 52

pharmaphorum

JANUARY 27, 2023

An additional note of optimism is that UK biotechs achieved pivotal milestones in their development, with Verona Pharma reporting a successful phase 3 trial for Ensifentrine, the first novel compound in over 10 years to address the ongoing needs of more than 380 million patients worldwide suffering from Chronic Obstructive Pulmonary Disease (COPD).

Pharma 52

Pharma Manufacturing Medicine Biopharma 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. The biggest impacts are likely to be felt by patients with PDPs that use coinsurance, which most plans do for specialty drugs.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 10, 2023

Many of the current existing therapies are often viewed by physicians as not optimal to addressing the needs of patients, and challenges remain such as improving patient compliance, safety profile, and addressing comorbidities of T2D. billion in sales in 2019, increasing to $136.2

Marketing 52

Marketing Physicians Sales Leads 52

Legacy MEDSearch

MAY 23, 2022

Surgeons are tethered to the surgical tower by a power cable and by a light cord that is often implicated in OR fires and patient burns. BN by 2027. The expected benefits include ease of use, improved OR efficiency, reduction in costs, and better patient outcomes. But we are at the dawn of a new era.

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate. The post Blockbusters in waiting: Clarivate’s drugs to watch in 2023 appeared first on.

FDA 52

FDA Marketing Pharma Sales 52

Legacy MEDSearch

JULY 24, 2023

Trial results are expected in 2027. SAINT therapy is the beginning of a revolution in psychiatry: fast, effective, and personalized treatments that give hope to patients who have failed to receive relief from traditional approaches,” said David Carreon, M.D.,

Medical 52

Medical Recruitment FDA Patients 52

PM360

JUNE 29, 2022

By 2025, sales of consumer health products are expected to reach $368bn, according to Euromonitor, encompassing everything from sleep aids to vitamins to sports nutrition products. Prescription refills can now be placed with a simple click on a patient portal. Reconsider the Role of Packaging.

Retail 97

Retail Marketing Healthcare Healthcare 97

PM360

SEPTEMBER 21, 2023

As a mission-driven company and digital healthcare leader, GoodRx has helped patients obtain an estimated 80 million prescriptions they otherwise may not have been able to afford. 1 We have been improving patient affordability for over a decade, across generic and brand medications, including specialty treatments—sometimes by more than 50%.

Prescription 52

Prescription Medical Patients Distribution 52

Medico Reach

FEBRUARY 8, 2023

Big data can help clinical trial design, allowing researchers to leverage genetic makeup, historical patient data, past trial results, demographics, and more to find the right participants. Pharma companies can utilize big data to predict the sale of a particular medicine owing to various demographic factors. billion by 2027.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Pharmaceutical Technology

APRIL 24, 2023

Biologics Versus Small Molecules By 2027 Forecast Sales Credit: GlobalData “CRDMOs have a deep understanding of protein chemistry, cell culture, and the impact of process conditions on yield and protein structure down to the smallest detail, including changes from lab to GMP scale.

Manufacturing 52

Manufacturing Food and Drug Administration Biopharma Sales 52

Star OUTiCO

FEBRUARY 18, 2022

For pharma and the NHS, this manifested itself in unprecedented changes to the way the latter delivers patient care, while the former – historically a little conservative on the digital uptake – became a beacon of inspiration for what’s possible when there is a strong sense of urgency. The ultimate benefactor, of course, is the patient.”

Pharma 52

Pharma Healthcare Healthcare Patients 52